Taofeek Owonikoko
塔欧菲克·奥沃尼科科
MD, PhD
Professor and Division Chief, Hematology/Oncology血液学/肿瘤学部主任兼教授
👥Biography 个人简介
Dr. Taofeek Owonikoko is a translational oncologist and division chief at UPMC Hillman Cancer Center, internationally recognized for advancing SCLC therapy. He led key trials of lurbinectedin and immunotherapy combinations, and his translational research bridges genomics with novel therapeutic strategies in thoracic malignancies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
SCLC Therapeutics: Lurbinectedin and Immunotherapy
Spearheaded clinical evaluation of lurbinectedin and atezolizumab-based combinations in SCLC, defining new second-line standards and integrating transcriptomic SCLC subtypes into therapeutic strategy.
Representative Works 代表性著作
Lurbinectedin as second-line treatment for patients with small-cell lung cancer
The Lancet Oncology (2020)
Basket trial establishing lurbinectedin efficacy in relapsed SCLC, supporting accelerated FDA approval and expanding therapeutic options.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 塔欧菲克·奥沃尼科科 的研究动态
Follow Taofeek Owonikoko's research updates
留下邮箱，当我们发布与 Taofeek Owonikoko（University of Pittsburgh Medical Center / UPMC Hillman Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment